Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Jazz Pharmaceuticals announced it will present data from ten presentations at the ASCO 2026 Annual Meeting, focusing on Ziihera for gastroesophageal adenocarcinoma and Zepzelca for small cell lung cancer. The Ziihera presentations include a rapid oral session on PD-L1 subgroup analysis from the Phase 3 HERIZON-GEA-01 trial.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.